Cargando…

Integrated Analysis of Gene Expression Profiles Associated with Response of Platinum/Paclitaxel-Based Treatment in Epithelial Ovarian Cancer

PURPOSE: This study aims to explore gene expression signatures and serum biomarkers to predict intrinsic chemoresistance in epithelial ovarian cancer (EOC). PATIENTS AND METHODS: Gene expression profiling data of 322 high-grade EOC cases between 2009 and 2010 in The Cancer Genome Atlas project (TCGA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Yong, Huang, Hao, Xiao, Zhen, Zhang, Wei, Cao, Yanfei, Qu, Like, Shou, Chengchao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531383/ https://www.ncbi.nlm.nih.gov/pubmed/23300757 http://dx.doi.org/10.1371/journal.pone.0052745

Ejemplares similares

Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition
por: Huang, Dongsheng, et al.
Publicado: (2016)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

N-Terminal Polypeptide of Annexin A2 Decreases Infection of Mycoplasma hyorhinis to Gastric Cancer Cells
por: Yuan, Shiqin, et al.
Publicado: (2016)

Activation of EGFR-PI3K-AKT signaling is required for Mycoplasma hyorhinis-promoted gastric cancer cell migration
por: Duan, Hongying, et al.
Publicado: (2014)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
por: Osman, Mohammed A., et al.
Publicado: (2016)

Cancer and embryo expression protein 65 promotes cancer cell growth and metastasis
por: JIN, GENGLIN, et al.
Publicado: (2015)

Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
por: Lam, Clarissa, et al.
Publicado: (2022)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Tumor Necrosis Factor-A Polymorphisms and Colorectal Cancer Risk: A Meta-Analysis
por: Min, Li, et al.
Publicado: (2014)

Extracellular gamma-synuclein promotes tumor cell motility by activating β1 integrin-focal adhesion kinase signaling pathway and increasing matrix metalloproteinase-24, -2 protein secretion
por: Liu, Caiyun, et al.
Publicado: (2018)

Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway
por: Liu, Jiafei, et al.
Publicado: (2019)

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
por: Sandercock, J, et al.
Publicado: (2002)

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
por: Kavanagh, John J, et al.
Publicado: (2010)

Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum
por: Melichar, Bohuslav, et al.
Publicado: (2007)

Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy
por: Smoter, Marta, et al.
Publicado: (2013)

Antibody Array Revealed PRL-3 Affects Protein Phosphorylation and Cytokine Secretion
por: Yang, Yongyong, et al.
Publicado: (2017)

Enhanced Efficacy of Neoadjuvant Chemotherapy with Nab-Paclitaxel and Platinum for Locally Advanced Cervical Cancer
por: Yu, Xiao-Li, et al.
Publicado: (2021)

Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth
por: Groeneweg, Jolijn W., et al.
Publicado: (2014)

The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
por: Zhao, Hong, et al.
Publicado: (2020)

Transcriptional Regulation of PES1 Expression by c-Jun in Colon Cancer
por: Xie, Wei, et al.
Publicado: (2012)

Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study
por: Wang, Liangliang, et al.
Publicado: (2023)

Phosphatase of regenerating liver-3 directly interacts with integrin β1 and regulates its phosphorylation at tyrosine 783
por: Tian, Wei, et al.
Publicado: (2012)

PRL-3 promotes cell adhesion by interacting with JAM2 in colon cancer
por: Lian, Shenyi, et al.
Publicado: (2016)

Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer
por: Girda, Eugenia, et al.
Publicado: (2022)

MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer
por: Silasi, Dan-Arin, et al.
Publicado: (2007)

Efficacy and safety of the combination of paclitaxel and platinum in advanced thymic carcinoma
por: Xu, Jian‐ping, et al.
Publicado: (2015)

Platinum-Taxol non-cross resistance in epithelial ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1995)

COPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer
por: Zhang, Hongqin, et al.
Publicado: (2022)

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer
por: Cantón-Romero, Juan Carlos, et al.
Publicado: (2017)

Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
por: Zhao, Hong, et al.
Publicado: (2021)

Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings
por: Tossetta, Giovanni
Publicado: (2022)

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
por: Cui, Qingli, et al.
Publicado: (2021)

Anti-PAI-1 Monoclonal Antibody Inhibits the Metastasis and Growth of Esophageal Squamous Cell Carcinoma
por: Zheng, Yutian, et al.
Publicado: (2023)

High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer
por: Du, Pei, et al.
Publicado: (2016)

Expression Profiles of Epithelial-Mesenchymal Transition-Associated Proteins in Epithelial Ovarian Carcinoma
por: Kim, Mi-Kyung, et al.
Publicado: (2014)

SERPINB3 in the Chicken Model of Ovarian Cancer: A Prognostic Factor for Platinum Resistance and Survival in Patients with Epithelial Ovarian Cancer
por: Lim, Whasun, et al.
Publicado: (2012)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer
por: Liu, Bo-lin, et al.
Publicado: (2014)

hMSH2 coordinated with the expression of E2F1 promotes platinum response in epithelial ovarian cancer
por: Hu, Xiao-qian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a9cu1s9p79ldgtosq15fg41dbm